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Introduction: Densiron® 68 is a high-density liquid used to tamponade inferior retinal 
detachments. We present a case series of 12 patients treated with Densiron as an intraocular 
tamponade agent.
Methods: A retrospective analysis of 12 eyes in 12 patients was carried out. The primary 
endpoint was anatomic reattachment of the retina following removal of Densiron oil.
Results: All patients had inferior detachments; 33% had associated proliferative vitreoretin-
opathy (PVR). Densiron was utilized as a primary agent in five patients (42%); the remaining 
patients had prior unsuccessful surgery for retinal reattachment, including pars plana vitrectomy, 
cryotherapy, laser, encirclement, gas (C3F8 or C2F6), or silicone oil. Eleven patients (91%) had 
successful reattachment of the retina at 3 months following removal of Densiron; one patient 
had extensive PVR, total retinal detachment, preretinal macula fibrosis, and chronic hypotony, 
and surgical intervention was unsuccessful. Six patients (50%) had raised intraocular pressure 
(IOP), resolving in the majority of cases following Densiron removal; two patients had long-
term raised IOP requiring topical or surgical therapy. Of the six phakic patients, 50% developed 
significant cataract in the operated eye. Of those with successful retinal reattachment, visual 
outcome was variable, with 36% patients gaining two to four lines on Snellen, 27% remaining 
objectively the same, and 36% losing one to two lines.
Conclusion: The anatomic success rate is high (91%) in patients requiring Densiron   tamponade 
for inferior retinal detachments with or without evidence of PVR either as a primary or   secondary 
intervention. A common complication is raised IOP; however, this most often resolves   following 
removal of the oil.
Keywords: intraocular tamponade, silicone oil, retinal detachment, retinal reattachments
Introduction
The complexities associated with inferior retinal detachments are well recognized. The 
difficulties with appropriate postoperative posturing and the predilection of the inferior 
retina for proliferative vitreoretinopathy (PVR) makes successful repair challenging.1 
These cases have often been repaired utilizing an intraocular tamponade of silicone oil; 
however, as the density of silicone oil is lower than that of water, the inferior retina is 
therefore only adequately supported if silicone oil fill is no less than 100%.
Perfluorohexyloctane (F6H8) has also been utilized within model systems due to 
its higher density; however, the tendency is for this compound to disperse into droplets 
and emulsify.2 The formation of Densiron® 68 (Fluoron Gmbh, Neu-Ulm, Germany) 
is a combination of the higher-density F6H8 and polydimethylsiloxane and has been 
developed for the purpose of intraocular tamponade for such cases (density 1.06 g/cm3; 
viscosity 1400 mPas at 25°C).Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
604
Hussain and Banerjee
The reports so far have been encouraging, with 
good anatomic results for both primary and secondary 
  procedures. Successful reattachment of the retina following 
use of   Densiron as a primary procedure for inferior retinal 
detachment complicated by PVR is reported for between 
91% and 95% of patients.3,4 For secondary procedures in 
patients with previous unsuccessful surgical interventions, 
anatomic success has understandably been more variable, 
reported as 46%–70%.5,6 These studies also demonstrated a 
significant improvement in visual acuity following surgical 
intervention.3,4,6
The main consequence reported is that of raised intraocu-
lar pressure (IOP); the rate of IOP . 30 mm Hg has been 
reported as being 10%–20%,3,5,7,8 generally resolving fol-
lowing removal of the agent.8,9 In comparison with silicone 
oil, the rate of raised IOP has been shown to be higher with 
Densiron in the initial few days postoperatively, but this 
equalizes after subsequent weeks.7 Although most cases of 
raised IOP resolve after removal of Densiron, the cases that 
are resistant seem to be more difficult to manage with topi-
cal agents than those secondary to silicone oil, occasionally 
requiring more invasive techniques.7
The aim of this report was to analyze the efficacy and 
rates of complications in patients with inferior retinal detach-
ments treated with Densiron as an intraocular tamponade in 
our unit.
Methods
A retrospective case note analysis was performed for all 
patients who had undergone retinal detachment repair utiliz-
ing Densiron over the period of October 2007 to August 2009, 
as identified by the theater logbook. Twelve patients were 
identified. All patients had rhegmatogenous inferior retinal 
detachments with or without clinical evidence of PVR; there 
were no patients with detachments secondary to trauma or 
any concurrent inflammatory ocular pathology. All patients 
with inferior detachments were included, whether this was 
a primary or secondary procedure.
There were no postoperative postural instructions. All 
patients were followed up for a minimum of 3 months fol-
lowing removal of the Densiron tamponade. Each record 
was assessed in respect of visual outcome, anatomic position 
of the retina, IOP, and any further intervention required for 
either redetachment or raised IOP.
Results
Patient age ranged from 54 years to 72 years; the male to 
female ratio was 7:5. Indications for use of the high-density 
oil were inferior retinal detachments (100%) and associated 
PVR (four patients; 33%). Densiron was utilized as a primary 
agent in five patients (42%); the remaining patients had prior 
unsuccessful surgery for retinal reattachment, including pars 
plana vitrectomy, cryotherapy, laser, encirclement, gas (C3F8 
or C2F6), or silicone oil. Time to removal of Densiron was 
46–247 days (manufacturer recommends 60 days).
Eleven patients (91%) had successful reattachment of 
the retina at 3 months following removal of Densiron; one 
patient had extensive PVR and total retinal detachment, 
macula preretinal fibrosis, and chronic hypotony, and surgi-
cal intervention was unsuccessful (Figure 1).
Six patients (50%) had raised IOP following Densiron 
administration, which resolved in the majority of cases fol-
lowing removal of the oil, two patients had long-term raised 
IOP requiring topical therapy, and one is awaiting Bearvelt 
tube insertion (Figure 2).
Six patients were pseudophakic; of the remaining six 
patients, three (50%) developed significant cataract in 
the operated eye (Figure 3). There were no cases of oil 
emulsification.
Of those with successful retinal reattachment, visual 
outcome was variable, with four (36%) patients gaining two 
to four lines on Snellen, three (27%) remaining objectively 
the same, and four patients (36%) losing one to two lines 
on Snellen (Figure 4). These were predominantly due to 
development of cataract or epiretinal membrane.
Table 1 gives a summary of the pre- and postoperative 
patient characteristics.
Discussion
Inferior retinal detachments are notoriously difficult to treat 
due to the increased preponderance of PVR. The use of other 
Successful retinal
reattachment
Retinal
redetachment
Figure 1 Anatomical reattachment following densiron removal.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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intraocular tamponade agents such as gas or silicone oil is 
complicated by reduced density in comparison with water. 
This predisposes to failure of anatomic retinal reattachment, 
as 100% vitreous fill and tamponade is essentially impossible. 
In addition, postoperative posturing for patients managed 
with these agents is consequently quite troublesome. We had 
no cases of band keratopathy or oil emulsification, which 
have both been described with silicone oil.10 Scleral buckles 
are an alternative therapy modality; however, not only are 
they more likely to be a cause of postoperative discomfort and 
inflammation but also they have an increased rate of induced 
myopia and ocular muscle imbalance. In addition, they are 
less straightforward in the management of larger and more 
posterior retinal tears or holes.
Densiron has been shown to have good anatomic results 
in patients with inferior retinal detachments, with or without 
the complication of PVR. The reported anatomic success rate 
for use of silicone oil as an intraocular tamponade varies 
from 75% to 90%;11,12 however, these results are not solely 
for inferior detachments and will therefore include superior 
pathologies that are adequately tamponaded by a less dense 
agent. In addition, high-density silicone oil has been trialled 
for inferior detachments with an anatomic success rate of 
79%–88%13,14 but with higher rates of emulsification.
The combination of silicone oil with a heavy liquid has 
enabled the formation of a tamponade agent that is denser 
than water and is therefore ideal for such inferior   pathologies. 
Posturing is not a problem, as an upright position is much 
preferred by patients and is utilized for the majority of 
the day. No postoperative postural instructions were given 
to the patients in this study. In comparison with silicone oil 
alone, Densiron is denser and therefore anatomically more 
effective for inferior pathology, but it also has comparable, 
if not better, rates of complications.
Our results, although in small numbers, are highly sug-
gestive of a high anatomic success rate whether the use of 
Densiron as an intraocular tamponade was as a primary agent 
or as a subsequent procedure following single or multiple 
failed surgical interventions. There were no cases of oil 
emulsification; however, the most common complication 
was raised IOP. The rate of persistent raised IOP follow-
ing Densiron removal was 16% (two patients). One patient 
was uncontrolled with topical therapy and required surgical 
intervention. This rate is consistent with previously reported 
rates utilizing silicone oil.15,16
Our current study numbers are small, and no direct con-
clusions can be drawn from a noncomparative study. Further 
research is required with comparative data with silicone 
oil in greater numbers. However, these preliminary results 
suggest effective results with use of Densiron for complex 
inferior retinal detachments, with safe outcomes comparable 
with previously reported outcomes with silicone oil. This 
compound may therefore be considered first line for such 
procedures.
Normal IOP
Raised IOP, resolution
with Densiron removal
Raised IOP, long term
topical Rx
Raised IOP, surgical
intervention
Figure 2 Postoperative raised intraocular pressure rates.
Cataract
Phakic, no
cataract
Figure 3 rates of cataract formation in phakic patients.
Improved vision
Unchanged vision
Reduction in vision
Figure 4 Change in visual acuity (measured by snellen) post Densiron removal.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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